R-2020 (R,S)-Rolipram, >99%

Synonyms : [Adeo] [ME-3167] [SB 95952] [ZK-62711]

  • Size
  • US $
  • £
  • ¥
  • 10 mg
  • 37
  • 33
  • 28
  • 4,100
  • Add to Cart Qty:
  • In stock
  • 25 mg
  • 51
  • 46
  • 39
  • 5,700
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 67
  • 61
  • 51
  • 7,500
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 98
  • 89
  • 75
  • 10,900
  • Add to Cart Qty:
  • In stock
  • 300 mg
  • 234
  • 214
  • 180
  • 26,100
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 585
  • 537
  • 451
  • 65,200
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 924
  • 848
  • 713
  • 103,000
  • Add to Cart Qty:
  • In stock
  • 5 g
  • 1,425
  • 1,308
  • 1,100
  • 158,900
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Click Here to see what Shipping and Handling Costs would be to Your Country
  • M.W. 275.34
  • C16H21NO3
  • [61413-54-5]
  • M.I. 14: 8251

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 50 mg/mL; soluble in ethanol at 25 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 50-100 µM; buffers, serum, or other additives may increase or decrease the aqueous solubilit. Disposal: A.

  • Rolipram is a selective phosphodiesterase 4 (PDE4) inhibitor. PDE4 enzymes inactivate cyclic AMP (cAMP) via hydrolysis to 5'-AMP.
  • Rolipram has two enantiomeric forms, R(-) and S(+). This product is the racemic mixture of the two enantiomers.
  • R-(-)-rolipram demonstrated a higher affinity for the PDE4 enzyme than S-(+)-rolipram, by about 8-fold in vitro and about 12- to 15-fold in vivo. Parker, C.A., et al. "Behaviour of [11C]R(-)- and [11C]S(+)-rolipram in vitro and in vivo, and their use as PET radiotracers for the quantificative assay of PDE4." Synapse 55: 270-279 (2005).
  • Rolipram is able to reverse ischemia-reperfusion (I/R)-induced increased microvascular permeability through cAMP phosphodiesterase (PDE) isozyme-selective inhibition. Barnard, J.W., et al. "Reversal of pulmonary capillary ischemia-reperfusion injury by rolipram, a cAMP phosphodiesterase inhibitor." J. Appl. Physiol. 77: 774-781 (1994).
  • Rolipram reduced the initial and late response to ovalbumin (OVA) in isolated strips of guinea-pig colonic smooth muscle. For both responses, the (S)-isomer (EC50 = approximately 1.0 µM) was about 10 fold less potent than the (R)-isomer (EC50 = approximately 0.1 µM). Grous, M. and Barnette, M. "Prevention by phosphodiesterase inhibitors of antigen-induced contraction of guinea-pig colonic smooth muscle." Br. J. Pharmacol. 111: 259-263 (1994).
  • Rolipram suppressed cardiopulmonary bypass-induced systemic inflammatory response syndrome, probably through the regulation of proinflammatory mediators by inhibiting phosphodiesterase type 4. Hamamoto, M., et al. "Suppressive effect of phosphodiesterase type 4 inhibition on systemic inflammatory responses after cardiopulmonary bypass." J. Artif. Organs 9: 144-148 (2006).
  • R6/2 mutant mice recapitulate human Huntington's disease in many ways. Rolipram has a neuroprotective effect in these mice. After treatment with rolipram, R6/2 mice survived longer and displayed less severe signs of neurological dysfunction. DeMarch, Z., et al. "Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease." Neurobiol. Dis. 30: 375-387 (2008).
  • Dopamine plays an essential role in the regulation of motor and cognitive functions. The effect of dopamine largely depends on the cAMP/PKA signaling cascade. Rolipram shows utility in neuropsychiatric and neurodegenerative disorders, posisbly by affecting dopamine neurotransmission. Nishi, A., et al. "Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum." J. Neurosci. 28: 10460-10471 (2008).
  • Another CAS number previously assigned to rolipram, namely 85416-74-6, has been deleted by CAS and is no longer in use.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
264